Symbol List Views
Stock Details
CHARTS
COMPANY NEWS
STOCK ANALYSIS
FUNDAMENTALS
HOLDINGS
Edit Symbol List
Symbol Lookup
VICL: Stock Quote & Summary Data
3.46%
| Last Sale | |
| Change Net / % |
|
| Best Bid / Ask | |
| 1y Target Est: | $ 6.50 |
| Today's High / Low | / |
| Share Volume | |
| 50 Day Avg. Daily Volume | 814,500 |
| Previous Close | $ 3.18 |
| 52 Wk High / Low | $ 5.51 / $ 1.04 |
| Shares Outstanding | 51,804,000 |
| Market Value | $ 159,038,280 |
| P/E Ratio | NE |
| Forward P/E (1yr) | NE |
| Earnings Per Share | $ -0.70 |
| Annualized Dividend | N/A |
| Ex Dividend Date | N/A |
| Dividend Payment Date | N/A |
| Current Yield | N/A |
| Beta | 1.82 |
| NASDAQ Official Open Price: | $ 3.16 |
| Date of NASDAQ Official Open Price: | Nov. 20, 2009 |
| NASDAQ Official Close Price: | $ 3.07 |
| Date of NASDAQ Official Close Price: | Nov. 20, 2009 |
Intraday Chart |
| 5d | 1m | 6m | 12m | More Charting |
Have a Question About VICL?
Ask your question about about Vical Incorporated (VICL) by typing it in the box below. You'll get direct responses from other members of the NASDAQ Answers community!
Hot Topics in NASDAQ Answers
The most popular questions & answers in the
NASDAQ Answers Community:
Company Description (as filed with the SEC)
We research and develop biopharmaceutical products based on our patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. We believe the following areas of research offer the greatest potential for our product development efforts: • Vaccines for use in high-risk populations for infectious disease targets for which there are significant U.S. needs; • Vaccines for general pediatric, adolescent and adult populations for infectious disease applications; and • Cancer vaccines or immunotherapies which complement our existing programs and core expertise. ... More ...
Links to all Vical Incorporated (VICL) Pages
Stock Analysis
Fundamentals
Holdings/Ownership
Company News for VICL |
||
|
Vical Added to NASDAQ Biotechnology Index - GlobeNewswire 11/16/2009 6:30AM |
||
|
Semi-Annual Changes to the NASDAQ Biotechnology Index - GlobeNewswire 11/13/2009 8:02PM |
||
|
Vical's DNA Vaccine Technology Addresses Challenges of Emerging Diseases - GlobeNewswire 11/10/2009 6:30AM |
||
|
Vical Inc. Q3 Loss Reduces - Quick Facts - RTT News 11/04/2009 6:49AM |
||
|
Vical Reports Third Quarter 2009 Financial Results and Progress in Key Development Programs - GlobeNewswire 11/04/2009 6:30AM |
||
|
Vical Announces News Release and Conference Call Schedule for Third Quarter 2009 Financial Results - GlobeNewswire 10/28/2009 6:30AM |
||
|
Vical to Present at BIOCOM Investor Conference - GlobeNewswire 10/27/2009 6:30AM |
Consensus Recommendation |
|
Analyst Info |
|
| Annual EPS Est: | $ -0.60 |
| Quarterly EPS Est: | $ -0.13 |
| PEG Ratio: | N/A |
| Mean Recommendation: View Summary/View All |
2.00 |
